We recently compiled a list of the Why These 15 Stocks Are Skyrocketing in 2025. In this article, we are going to take a look at where AtriCure, Inc. (NASDAQ:ATRC) stands against the other stocks that ...

The innovation showcased at CES highlights how practical solutions can meet niche, but impactful, health challenges. These ...

According to a 2023 PwC report, the AI market in healthcare was valued at $11 billion and is expected to grow to $188 billion by 2030. On January 21st, Oracle Co-founder Larry Ellison said during a ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...

For people with atrial fibrillation (Afib), investigational abelacimab proved to be a potent dual factor XI/XIa inhibitor with much lower safety risks compared with a direct oral anticoagulant (DOAC), ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

A new national survey found that while many Americans use a device to monitor their heart, few share that data with their doctor.

Much has changed since the 2013 document came out, with new information on pacing devices, techniques, and more.

Intelliguard & Codonics are offering an integrated system tracking medication from receipt at the hospital to it being properly discarded ...